PhD Scientific Days 2023

Translational Medicine - Posters P

Use of Cu-64 to Radiolabel and Track Bacterial Outer Membrane Vesicles In Vivo With PET

Előadó neve

Shailaja, Kanni Das

Neptun code

UG5346

Előadó munkahelye

Semmelweis University

Előadó telefonszáma

+36204779504

Előadó e-mail címe

kanni.shailaja@phd.Semmelweis.hu

Az előadás címe

Use of Cu-64 to Radiolabel and Track Bacterial Outer Membrane Vesicles In Vivo With PET

Szerző(k) neve és munkahelye

Kanni Das Shailaja1,2*, Dávid Szöllősi2*, Polett Hajdrik2, Zoltán Varga2, Hedvig Tordai2, Krisztián Szigeti2, Ildikó Horváth1,2, Noémi Kovács1, Domokos. Máthé1,2,3
* Equal contributing authors
1: CROMed Ltd, Budapest, Hungary,
2: Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary
3: In Vivo Imaging ACF, Hungarian Center of Excellence for Molecular Medicine, Szeged, Hungary

Bemutatás módja

Poszter

Szekció

Translational Medicine - Posters P

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: Bacterial outer membrane vesicles (OMVs) are nano-sized extracellular vesicles (EVs) released by Gram-negative bacteria into their environment. SpyCatcher (SpC) is a protein that forms a spontaneous isopeptide bond with the peptide tag SpyTag (SpT).
Aims: Designing a novel approach for the radiolabeling and quantitative molecular imaging of bacterial outer membrane vesicles (OMVs).
Method: SpyCatcher is anchored to the OMV surface using surface display systems based on bacterial autotransporters AIDA and Hbp that are expressed using a novel genetically engineered E. coli BL21(DE3) ΔnlpI, ΔlpxM strain. Cu-64 is an appropriate isotope for radiolabeling and tracking different protein, peptide or particulate systems in biological in vivo studies.
Results: Cu-64 half-life of 12.7 hours allows for flexible detection of the positron-emitting decay using appropriately sensitive imaging systems up to 5 days after injection. SpT was radiolabeled with Cu-64 through a macrocylic chelator, then purified and incubated along with OMV-s. After incubation and size exclusion based filtration, radiolabeled OMV-s were produced and ready for in vivo use. Biodistribution of radiolabeled OMVs in mice was measured using positron emission tomography (PET) following intravenous administration. Conclusion: The novel method can serve as a basis for a general OMV radiolabeling scheme and could be integrated into vaccine- and drug-carrier development based on bioengineered OMVs.
Funding: European Union’s Horizon 2020 Research And Innovation Program, grant
agreement No 739593: HCEMM, supported by EU Programme: H2020-EU.4.a.

University and Doctoral School

Semmelweis University, Doctoral School of Theoretical and Translational Medicine

Supervisor

Dr Domokos Mathe

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7482

Start

10:48

End

10:53

Authors (legacy)

Kanni Das Shailaja1,2*, Dávid Szöllősi2*, Polett Hajdrik2, Zoltán Varga2, Hedvig Tordai2, Krisztián Szigeti2, Ildikó Horváth1,2, Noémi Kovács1, Domokos. Máthé1,2,3
* Equal contributing authors
1: CROMed Ltd, Budapest, Hungary,
2: Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary
3: In Vivo Imaging ACF, Hungarian Center of Excellence for Molecular Medicine, Szeged, Hungary